2024 연구성과 (4 / 286)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI ⓘ FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
○ ○ Article ⓘ Effect of extracorporeal shock wave therapy on the microbial community in burn scars: retrospective case-control study ⓘ Background:The effectiveness of extracorporeal shock wave therapy (ESWT) has been demonstrated in various medical fields, including burn medicine. It promotes wound healing, improves blood flow, and modulates the inflammatory responses. The recovery speed and outcomes of skin diseases are influenced by the skin microbiome; however, studies examining the effects of specific treatments on the skin microbiome are lacking. This study investigated the impact of ESWT on the skin microbiome of burn patients, focusing on the microbial diversity and community structure within burn scars. Materials and methods:In the retrospective case-control study, 19 patients with burn scars were treated with ESWT, and changes in their skin microbiome were evaluated. ESWT was administered weekly for 3 months, and samples were collected from the ESWT-treated burn scars and untreated normal skin. Blood chemistry, and pain and itching scores were evaluated during sample collection. The collected samples were then subjected to 16S rRNA sequencing. Microbial community analysis was conducted using the QIIME2 and R packages. Results:After ESWT, changes in alpha diversity indices were observed in burn scars. Faith phylogenetic diversity (P<0.05) and observed features (P<0.01) increased, whereas the evenness index decreased (P<0.01); no marked changes were noted in untreated skin. Beta diversity analysis showed stable microbial community structures in both the treated and untreated areas. A considerable increase in Micrococcus and Staphylococcus abundance was observed. Network analysis revealed a more open microbial network structure after ESWT, indicating adaptive changes in the microbial community. Conclusion:ESWT enhances microbial diversity and modifies microbial community structure in burn scars, promoting a more balanced and functionally supportive microbiome. ESWT aids in scar remodeling and positively influences skin microbiome dynamics, contributing to improved skin health and recovery. ⓘ Jung, Yeongyun; Kim, Ryeong-Hui; Lee, Eun Kyung; Seo, Cheong Hoon; Joo, So Young; Shin, Jae-Ho; Cho, Yoon Soo ⓘ Hallym Univ, Hangang Sacred Heart Hosp, Burn Inst, Coll Med, Chunchon, South Korea; Hallym Univ, Coll Med, Hangang Sacred Heart Hosp, Dept Rehabil Med, Seoul, South Korea; Kyungpook Natl Univ, NGS Core Facil, Daegu, South Korea ⓘ shin, Jaeho/K-6792-2013; Cho, Yoon Soo/JXL-2899-2024; Lee, Eunkyung/AAG-1192-2019; Seo, Cheong/V-4059-2019 ⓘ 57197833801; 57222756419; 57230063400; 15045712900; 57162237000; 57224125922; 56059636900 ⓘ jyg1076@hallym.ac.kr;rrhee22@gmail.com;eunlee0617@gmail.com;chseomd@gmail.com;anyany98@naver.com;jhshin@knu.ac.kr;yschorm@hallym.ac.kr; ⓘ INTERNATIONAL JOURNAL OF SURGERY ⓘ INT J SURG ⓘ 1743-9191 1743-9159 110 12 SCIE SURGERY ⓘ 2024 10.1 0.8 0.84 2025-05-07 ⓘ 3 2 burn scars; extracorporeal shock wave therapy; microbial community structure; microbial diversity; skin microbiome ⓘ SKIN MICROBIOTA ⓘ ⓘ Adult; Burns; Case-Control Studies; Cicatrix; Extracorporeal Shockwave Therapy; Female; Humans; Male; Microbiota; Middle Aged; Retrospective Studies; Skin; Wound Healing; Young Adult; adult; burn; case control study; complication; etiology; female; human; male; microbiology; microflora; middle aged; procedures; retrospective study; scar; shock wave therapy; skin; therapy; wound healing; young adult ⓘ English 2024 2024-12 10.1097/js9.0000000000002083 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Improved order in Hilfer fractional differential systems: Solvability and optimal control problem for hemivariational inequalities ⓘ The main objective of this study is to analyze the optimal control results and solvability concerning Hilfer fractional differential hemivariational inequalities within the range of (1 < rho 2). Initially, we explore the solvability of a mild solutions for the Hilfer fractional hemivariational inequality. Subsequently, we investigate the optimal control strategies for the given problems by employing cost functionals, cosine operators, mild solutions, the fixed point method for multivalued functions, and a generalized Clarke subdifferential approach. To illustrate our findings, we provide a practical example and a filter diagram. ⓘ Raja, Marimuthu Mohan; Vijayakumar, V.; Veluvolu, Kalyana Chakravarthy ⓘ Kyungpook Natl Univ, Sch Elect Engn, Daegu 41566, South Korea; Vellore Inst Technol, Sch Adv Sci, Dept Math, Vellore 632014, Tamil Nadu, India ⓘ VIJAYAKUMAR, Dr. VELUSAMY/A-7860-2015; Veluvolu, Kalyana Chakravarthy/C-6366-2011; Veluvolu, Kalyana/C-6366-2011; Mohan Raja, Marimuthu/HGB-7810-2022 ⓘ 57327789300; 55401798400; 8703318200 ⓘ raja1605@knu.ac.kr;vijayakumarv@vit.ac.in;veluvolu@ee.knu.ac.kr; ⓘ CHAOS SOLITONS & FRACTALS ⓘ CHAOS SOLITON FRACT ⓘ 0960-0779 1873-2887 188 SCIE MATHEMATICS, INTERDISCIPLINARY APPLICATIONS;PHYSICS, MATHEMATICAL;PHYSICS, MULTIDISCIPLINARY ⓘ 2024 5.6 0.8 0.53 2025-05-07 ⓘ 4 4 Hilfer fractional derivative; Optimal control; Semigroup theory; Hemivariational inequalities; Filter diagram; Fixed point theorem ⓘ DELAY EVOLUTION INCLUSIONS; APPROXIMATE CONTROLLABILITY; EXISTENCE; EQUATIONS ⓘ Filter diagram; Fixed point theorem; Hemivariational inequalities; Hilfer fractional derivative; Optimal control; Semigroup theory ⓘ Differential systems; Filter diagram; Fixed points theorems; Fractional derivatives; Fractional differential; Hemivariational inequality; Hilfe fractional derivative; Mild solution; Optimal controls; Semi-group theory ⓘ English 2024 2024-11 10.1016/j.chaos.2024.115558 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Long-term cardiovascular risk reduction after gastric cancer surgery: a nationwide cohort study ⓘ Background: Gastrectomy for gastric cancer is associated with postoperative changes in cardiovascular risk factors, however, the impact of gastrectomy on cardiovascular events remains unclear. The authors assessed the incidence of cardiovascular events between patients undergoing gastrectomy or endoscopic resection for gastric cancer, and the general population. Materials and methods: This retrospective nationwide cohort study included patients with gastric cancer undergoing gastrectomy (n=37 698), endoscopic resection (n=2773), and matched control population (n=161 887) between 2004 and 2013. The authors included patients without a history of cancer other than gastric cancer, myocardial infarction, or ischemic stroke. The primary outcome was the incidence of major adverse cardiovascular events (MACE) such as acute myocardial infarction, revascularization, or acute ischemic stroke, in patients with gastric cancer. Results: Among patients who underwent gastrectomy for gastric cancer, 2.9% (4.69 per 1000 person-years) developed novel MACE within the 1-year follow-up period. The gastrectomy group demonstrated a significantly decreased risk for MACE than the control population [hazard ratio (HR), 0.65; 95% CI: 0.61-0.69; P<0.001). Among the patients undergoing endoscopic resection for gastric cancer, 5.4% (8.21 per 1000 person-years) developed novel MACE within the 7-year follow-up period. The risk for MACE in the endoscopic resection group was not significantly different from the control population. Conclusion: Patients with gastric cancer who have undergone gastrectomy exhibit a reduced risk of cardiovascular diseases in comparison to the general population. In contrast, the risk for cardiovascular diseases in patients with gastric cancer who underwent endoscopic resection did not demonstrate a significant difference in cardiovascular risk in comparison to the general population. ⓘ Kwon, Yeongkeun; Kim, Dohyang; Kim, Sangwoo; Ha, Jane; Hwang, Jinseub; Park, Sungsoo; Kwon, Jin-Won ⓘ Korea Univ, Coll Med, Div Foregut Surg, 73,Goryeodae Ro, Seoul 02841, South Korea; Korea Univ, Anam Hosp, Ctr Obes & Metab Dis, Seoul, South Korea; Daegu Univ, Dept Stat, Gyongsan, Gyeongbuk, South Korea; Korea Univ, Coll Med, Dept Med, Seoul, South Korea; Kyungpook Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, BK21 FOUR Community Based Intelligent Novel Drug D, 80,Daehakro, Daegu 41566, South Korea; Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA USA ⓘ Park, Sun-Young/B-4634-2014 ⓘ 55970203000; 57218821860; 59237264800; 57217000677; 57189231296; 57187346700; 16202951700 ⓘ kwon.yeongkeun@gmail.com;gj1705@naver.com;socalman64@naver.com;janeha0124@gmail.com;hjs04090409@gmail.com;kugspss@korea.ac.kr;jwkwon@knu.ac.kr; ⓘ INTERNATIONAL JOURNAL OF SURGERY ⓘ INT J SURG ⓘ 1743-9191 1743-9159 110 7 SCIE SURGERY ⓘ 2024 10.1 0.8 0 2025-05-07 ⓘ 0 0 cardiovascular risk; endoscopic resection; gastrectomy; gastric cancer ⓘ GASTRECTOMY; ASSOCIATION; SENSITIVITY; MANAGEMENT; REMISSION ⓘ ⓘ Adult; Aged; Cardiovascular Diseases; Cohort Studies; Female; Gastrectomy; Heart Disease Risk Factors; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Risk Factors; Stomach Neoplasms; adult; adverse event; aged; cardiovascular disease; cohort analysis; epidemiology; etiology; female; gastrectomy; heart disease risk factor; human; incidence; male; middle aged; postoperative complication; prevention and control; procedures; retrospective study; risk factor; stomach tumor; surgery ⓘ English 2024 2024-07 10.1097/js9.0000000000001404 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Perioperative textbook outcomes of minimally invasive pancreatoduodenectomy: a multicenter retrospective cohort analysis in a Korean minimally invasive pancreatic surgery registry ⓘ Background: The aim of this study is to investigate the perioperative composite textbook outcomes of pancreatic surgery after minimally invasive pancreatoduodenectomy (MIPD). Materials and methods: The cohort study was conducted across 10 institutions and included 1552 patients who underwent MIPD registered with the Korean Study Group on Minimally Invasive Pancreatic Surgery between May 2007 and April 2020. We analyzed perioperative textbook outcomes of pancreatic surgery after MIPD. Subgroup analyses were performed to assess outcomes based on the hospital volume of MIPD. Results: Among all patients, 21.8% underwent robotic pancreatoduodenectomy. High-volume centers (performing >20 MIPD/year) performed 88.1% of the procedures. The incidence of clinically relevant postoperative pancreatic fistula was 11.5%. Severe complications (Clavien-Dindo grade >= IIIa) occurred in 15.1% of the cases. The 90-day mortality rate was 0.8%. The mean hospital stay was 13.7 days. Textbook outcomes of pancreatic surgery success were achieved in 60.4% of patients, with higher rates observed in high-volume centers than in low-volume centers (62.2% vs. 44.7%, P<0.001). High-volume centers exhibited significantly lower conversion rates (5.4% vs. 12.5%, P=0.001), lower 90-day mortality (0.5% vs. 2.7%, P=0.001), and lower 90-day readmission rates (4.5% vs. 9.6%, P=0.006) than those low-volume centers. Conclusion: MIPD could be performed safely with permissible perioperative outcomes, including textbook outcomes of pancreatic surgery, particularly in experienced centers. The findings of this study provided valuable insights for guiding surgical treatment decisions in periampullary disease. ⓘ Kwon, Jaewoo; Kang, Chang Moo; Jang, Jin-Young; Yoon, Yoo-Seok; Kwon, Hyung Jun; Choi, In Seok; Kim, Hee Joon; Shin, Sang Hyun; Kang, Sang Hyun; Moon, Hyung Hwan; Hwang, Dae Wook; Kim, Song Cheol ⓘ Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Surg, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Hepatobiliary & Pancreat Surg, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Div Hepatobiliary Pancreat Surg, Dept Surg, Samsung Med Ctr,Sch Med, Seoul, South Korea; Univ Ulsan, Coll Med, Dept Surg, Div Hepatobiliary & Pancreat Surg, Seoul 138736, South Korea; Asan Med Ctr, Seoul, South Korea; Konyang Univ, Konyang Univ Hosp, Coll Med, Dept Surg, Daejeon, South Korea; Chonnam Natl Univ, Dept Surg, Div Hepatopancreato Biliary Surg, Med Sch, Gwangju, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Surg, Seongnam, South Korea; Inje Univ, Busan Paik Hosp, Coll Med, Dept Surg, Busan, South Korea; Kosin Univ, Coll Med, Dept Surg, Busan, South Korea; Kyungpook Natl Univ, Med Ctr, Dept Surg, Daegu, South Korea; Univ Ulsan, Dept Surg, Div Hepatobiliary & Pancreat Surg, Coll Med,Brain Korea 21 Plus, 88,Olymp Ro 43-Gil, Seoul 05505, South Korea; Asan Med Ctr, 88,Olymp Ro 43-Gil, Seoul 05505, South Korea ⓘ ; Yoon, Yoo-Seok/AAD-4820-2020 ⓘ 57202913816; 34968209400; 7402965187; 7402126748; 59579184900; 36099905300; 55650398000; 36109355100; 57219307879; 55540280900; 24175981100; 57984761900 ⓘ skunlvup@naver.com;CMKANG@yuhs.ac;jangjy4@snu.ac.kr;arsyun@gmail.com;kwonhj95@naver.com;choiins@kyuh.ac.kr;heejoonkim@jnu.ac.kr;surgeonssh@gmail.com;stapex@naver.com;ras99m@naver.com;dwhwang@amc.seoul.kr;drksc@amc.seoul.kr; ⓘ INTERNATIONAL JOURNAL OF SURGERY ⓘ INT J SURG ⓘ 1743-9191 1743-9159 110 7 SCIE SURGERY ⓘ 2024 10.1 0.8 0.84 2025-05-07 ⓘ 3 1 minimally invasive pancreatoduodenectomy; textbook outcome of pancreatic surgery ⓘ INTERNATIONAL STUDY-GROUP; DEFINITION; CLASSIFICATION; TUMORS ⓘ ⓘ Adult; Aged; Female; Hospitals, High-Volume; Humans; Length of Stay; Male; Middle Aged; Minimally Invasive Surgical Procedures; Pancreatic Fistula; Pancreaticoduodenectomy; Postoperative Complications; Registries; Republic of Korea; Retrospective Studies; Robotic Surgical Procedures; Treatment Outcome; adult; adverse event; aged; clinical trial; epidemiology; etiology; female; high volume hospital; human; length of stay; male; middle aged; minimally invasive surgery; multicenter study; pancreas fistula; pancreaticoduodenectomy; postoperative complication; procedures; register; retrospective study; robot assisted surgery; South Korea; treatment outcome ⓘ English 2024 2024-07 10.1097/js9.0000000000001390 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Risk of congestive heart failure and mortality following lymphovenous anastomosis: a nationwide population-based retrospective cohort study ⓘ Background: Lymphovenous anastomosis (LVA) enables lymphatic fluid to drain into the venous system. However, no study has investigated the association between LVA and heart failure (HF) caused by fluid overload in the blood circulating system. The purpose of our study was to determine whether LVA increases the risk of HF and mortality. Material and methods: This nationwide retrospective study evaluated a total of 1400 lymphedema patients who underwent LVA and two control cohorts with 28 000 lymphedema who did not undergo LVA and 70 000 age-matched and sex-matched participants from the Korean National Health Insurance database were included. Blood pressure, body mass index (BMI), glucose and cholesterol levels, smoking history, and comorbidities were obtained during National Health Insurance Service - Health Screening (NHIS-HealS). The incidence, adjusted risk for HF, and mortality were evaluated. Results: Adjusted HRs for HF were 1.20 (confidence interval [CI], 1.03-1.40) and 1.30 (CI, 1.12-1.50), referenced by the general population control cohort and patients with lymphedema without LVA, respectively. In age, sex, BMI, and smoking status-stratified analyses, heightened risk of HF was evident across all sexes, spanning both young and old age groups, encompassing individuals with various smoking statuses, and those with a BMI of 18.5 or higher. Among these groups, the risk was notably greater in males compared to females, higher in younger individuals as opposed to older ones, and further elevated within the BMI range of 18.5-25. Conclusions: LVA is associated with an increased HF risk, independent of cardiovascular risk factors and associated comorbidities. This association is prominent in participants aged = 18.5 kg/m(2)) group. Among patients with lymphedema, LVA did not significantly affect mortality. ⓘ Lee, Joon Seok; Kang, Hyun Su; Chung, Jae-Ho; Ryu, Jeong Yeop ⓘ Kyungpook Natl Univ, Sch Med, Dept Plast & Reconstruct Surg, 680 Gukchaebosanro, Daegu 41405, South Korea; Korea Univ Hosp, Dept Plast & Reconstruct Surg, Seoul, South Korea ⓘ LEE, JIN/Q-3108-2018; Ryu, Jeong Yeop/GLQ-9419-2022 ⓘ 56496041000; 58890125800; 57218683056; 56366349400 ⓘ leejspo@knu.ac.kr;hskhs0102@naver.com;cjh665@gmail.com;prsryu@knu.ac.kr; ⓘ INTERNATIONAL JOURNAL OF SURGERY ⓘ INT J SURG ⓘ 1743-9191 1743-9159 110 2 SCIE SURGERY ⓘ 2024 10.1 0.8 3.35 2025-05-07 ⓘ 4 4 heart failure; interdisciplinary research; lymphaticovenous anastomosis; lymphedema ⓘ VOLUME OVERLOAD; BLOOD ⓘ ⓘ Anastomosis, Surgical; Female; Heart Failure; Humans; Lymphatic Vessels; Lymphedema; Male; Retrospective Studies; anastomosis; female; heart failure; human; lymph vessel; lymphedema; male; retrospective study ⓘ English 2024 2024-02 10.1097/js9.0000000000000946 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Surgical quality assessment for the prospective study of oncologic outcomes after laparoscopic modified complete mesocolic excision for nonmetastatic right colon cancer (PIONEER study) ⓘ Background:The modified complete mesocolic excision (mCME) procedure for right-sided colon cancer is a tailored approach based on the original complete mesocolic excision (CME) methodology. Limited studies evaluated the safety and feasibility of laparoscopic mCME using objective surgical quality assessments in patients with right colon cancer. The objectives of the PIONEER study were to evaluate oncologic outcomes after laparoscopic mCME and to identify optimal clinically relevant endpoints and values for standardizing laparoscopic right colon cancer surgery based on short-term outcomes of procedures performed by expert laparoscopic surgeons.Materials and methods:This is an ongoing prospective, multi-institutional, single-arm study conducted at five tertiary colorectal cancer centers in South Korea. Study registrants included 250 patients scheduled for laparoscopic mCME with right-sided colon adenocarcinoma (from the appendix to the proximal half of the transverse colon). The primary endpoint was 3-year disease-free survival. Secondary outcomes included 3-year overall survival, incidence of morbidity in the first 4 weeks postoperatively, completeness of mCME, central radicality, and distribution of metastatic lymph nodes. Survival data will be available after the final follow-up date (June 2024).Results:The postoperative complication rate was 12.9%, with a major complication rate of 2.7%. In 87% of patients, central radicality was achieved with dissection at or beyond the level of complete exposure of the superior mesenteric vein. Mesocolic plane resection with an intact mesocolon was achieved in 75.9% of patients, as assessed through photographs. Metastatic lymph node distribution varied by tumor location and extent. Seven optimal clinically relevant endpoints and values were identified based on the analysis of complications in low-risk patients.Conclusions:Laparoscopic mCME for right-sided colon cancer produced favorable short-term postoperative outcomes. The identified optimal clinically relevant endpoints and values can serve as a reference for evaluating surgical performance of this procedure. ⓘ Yang, Seung Yoon; Kim, Min Jung; Kye, Bong-Hyeon; Han, Yoon Dae; Cho, Min Soo; Park, Ji Won; Jeong, Seung-Yong; Song, Seung Ho; Park, Jun Seok; Park, Soo Yeun; Kim, Jin; Min, Byung Soh ⓘ Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; Catholic Univ Korea, Sch Med, Dept Surg, Seoul, South Korea; Korea Univ, Coll Med, Dept Surg, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea; Yonsei Univ, Coll Med, Severance Hosp, Dept Surg,Seodaemun Ku, 50 Yonsei Ro, Seoul 120752, South Korea ⓘ ; KIM, JEONGSEON/AAA-4643-2022; Han, Yoondae/W-1325-2019; Jeong, Seung-Yong/J-5643-2012; Park, Ji Won/JCD-9105-2023; Park, Joonhong/AAZ-9885-2020; Kim, You Sun/B-2881-2015 ⓘ 57193152513; 56984393300; 36022461900; 56877960900; 37664649800; 57222044570; 7402425099; 57221771693; 35226761100; 58940733300; 55720304300; 35269560900 ⓘ syyy2000@yuhs.ac;surgeon.mjkim@gmail.com;ggbong@catholic.ac.kr;acylyoon@yuhs.ac;nagase96@yuhs.ac;sowisdom@gmail.com;00916@snuh.org;jojocrom33@gmail.com;parkjs0802@knu.ac.kr;psy-flower@hanmail.net;mrgs@korea.ac.kr;bsmin@yuhs.ac; ⓘ INTERNATIONAL JOURNAL OF SURGERY ⓘ INT J SURG ⓘ 1743-9191 1743-9159 110 3 SCIE SURGERY ⓘ 2024 10.1 0.8 3.35 2025-05-07 ⓘ 4 4 modified complete mesocolic excision; right-sided colon cancer; short-term outcomes; standardized surgery ⓘ CENTRAL VASCULAR LIGATION; TERM-OUTCOMES; SURGERY; RESECTION; ASSOCIATION; DISSECTION; SURVIVAL; COHORT ⓘ ⓘ Adenocarcinoma; Colectomy; Colonic Neoplasms; Humans; Laparoscopy; Lymph Node Excision; Mesocolon; Prospective Studies; Treatment Outcome; adenocarcinoma; colectomy; colon tumor; human; laparoscopy; lymph node dissection; mesocolon; procedures; prospective study; treatment outcome ⓘ English 2024 2024-03 10.1097/js9.0000000000000956 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Synchronization of Kuramoto-Sakaguchi model with the distributed time interactions ⓘ The synchronous behavior of Kuramoto-Sakaguchi models with distributed time-delayed interactions is investigated. We prove complete and partial phase synchronization for both the distributed semi time-delay model and the full time-delay model. Additionally, we present several numerical experiments supporting our main results and illustrating interesting patterns. ⓘ Hsia, Chun-Hsiung; Jung, Chang-Yeol; Kwon, Bongsuk; Moon, Sunghwan ⓘ Inst Appl Math Sci, Dept Math, Taipei, Taiwan; Natl Taiwan Univ, Natl Ctr Theoret Sci, Taipei 10617, Taiwan; Ulsan Natl Inst Sci & Technol, Dept Math Sci, Ulsan 44919, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Math, Daegu 41566, South Korea ⓘ ⓘ 16549439100; 8362020700; 35366637500; 56063426100 ⓘ willhsia@math.ntu.edu.tw;cjung@unist.ac.kr;bkwon@unist.ac.kr;sunghwan.moon@knu.ac.kr; ⓘ CHAOS SOLITONS & FRACTALS ⓘ CHAOS SOLITON FRACT ⓘ 0960-0779 1873-2887 179 SCIE MATHEMATICS, INTERDISCIPLINARY APPLICATIONS;PHYSICS, MATHEMATICAL;PHYSICS, MULTIDISCIPLINARY ⓘ 2024 5.6 0.8 2.13 2025-05-07 ⓘ 4 4 Kuramoto; Phase synchronization; Distributed time delay interactions ⓘ COUPLED OSCILLATORS; DELAY; FREQUENCY; DISCRETE; NETWORKS ⓘ Distributed time delay interactions; Kuramoto; Phase synchronization ⓘ Time delay; Timing circuits; Distributed time; Distributed time delay interaction; Distributed time delays; Kuramoto; Numerical experiments; Partial phase synchronizations; Phase synchronization; Time delay model; Time-delayed interactions; Synchronization ⓘ English 2024 2024-02 10.1016/j.chaos.2023.114422 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ The impact of social interventions on COVID-19 spreading based on multilayer commuter networks ⓘ From March to June 2022, Shanghai was struck by a new coronavirus variant, Omicron, resulting in the infected cases of at least 600,000 people. Despite implementing a strict containment policy of city-wide silence (i.e., residents were not allowed to go out unless necessary), the outbreak cannot be effectively prevented within a short period of time. A significant academic and practical question is: how could we prevent and control outbreak of COVID-19 in large, densely populated cities like Shanghai? It is necessary to develop a rational epidemic spreading model for large cities, in order to accurately predict the trend of disease and quantitatively assess the impact of non-pharmaceutical interventions. In this paper, a multilayer commuter metapopulation network model is constructed to capture commuting flows and the size of epidemic outbreak during commuting between districts. The model accurately predicts epidemic spreading in each district of Shanghai. Assuming strict city-wide lockdowns, with each district locked down and limited inter-district commuting as social zones, simulations demonstrate significant suppression of outbreaks due to social-level interventions. For example, a 1 -fold increase in PCR (Polymerase Chain Reaction) testing efficiency reduces the size of epidemic outbreak by approximately 70%. Larger districts require stricter controls to prevent exponential growth. Lockdowns effectively prevent epidemic outbreak at low disease rates but less so at high rates. Liberalized policies lead to varied outbreak trends, with economically developed regions peaking earlier due to higher population densities. This study provides a comprehensive framework for quantitatively evaluating the impact of social and regional controls on urban epidemics. ⓘ Zeng, Lang; Chen, Yushu; Liu, Yiwen; Tang, Ming; Liu, Ying; Jin, Zhen; Do, Younghae; Pelinovsky, E.; Kirillin, M.; Macau, E. ⓘ East China Normal Univ, Sch Phys & Elect Sci, Shanghai 200241, Peoples R China; Kyungpook Natl Univ, Nonlinear Dynam & Math Applicat Ctr, Dept Math, Daegu 41566, South Korea; East China Normal Univ, Shanghai Key Lab Multidimens rumor Proc, Shanghai 200241, Peoples R China; Southwest Petr Univ, Sch Comp Sci, Chengdu 610500, Peoples R China; Shanxi Univ, Sch Math Sci, Taiyuan 030006, Peoples R China; Shanxi Univ, Complex Syst Res Ctr, Taiyuan 030006, Peoples R China; Shanxi Key Lab Math Tech & Big Data Anal Dis Contr, Taiyuan 030006, Peoples R China; Natl Res Univ, Higher Sch Econ, Bolshaya Pechorskaya st 25-12, Nizhnii Novgorod 603155, Russia; RAS, Inst Appl Phys, Ulyanov St 46, Nizhnii Novgorod 603950, Russia; Univ Fed Sao Paulo, BR-04021001 Sao Paulo, Brazil ⓘ Do, Younghae/G-3522-2011; Zeng, Lang/KLC-2236-2024; jin, zhen/B-6563-2015 ⓘ 57219643973; 58612535300; 59184628600; 14421628700; 56641911300; 9247719500; 7103101109; 7004951110; 8963798300; 6701767295 ⓘ tangminghan007@gmail.com; ⓘ CHAOS SOLITONS & FRACTALS ⓘ CHAOS SOLITON FRACT ⓘ 0960-0779 1873-2887 185 SCIE MATHEMATICS, INTERDISCIPLINARY APPLICATIONS;PHYSICS, MATHEMATICAL;PHYSICS, MULTIDISCIPLINARY ⓘ 2024 5.6 0.8 1.07 2025-05-07 ⓘ 3 4 Epidemic spreading; COVID-19; Multilayer commuter networks; Non-pharmaceutical interventions ⓘ ⓘ COVID-19; Epidemic spreading; Multilayer commuter networks; Non-pharmaceutical interventions ⓘ Economic and social effects; Multilayers; Polymerase chain reaction; Population statistics; Coronaviruses; Epidemic spreading; Large cities; Metapopulation networks; Multilayer commuter network; Network models; Non-pharmaceutical interventions; Short periods; Simulation demonstrate; Testing efficiency; COVID-19 ⓘ English 2024 2024-08 10.1016/j.chaos.2024.115160 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Fabrication of MoS2 restrained magnetic chitosan polysaccharide composite for the photocatalytic degradation of organic dyes ⓘ Chitosan (CS) polysaccharide is expected to exhibit greater ionic conductivity, which can be attributed to its increased amino group content when it is blended with different semiconducting materials. Herein, the work used this conducting ability of chitosan and prepared a heterogeneous MoS2-induced magnetic chitosan (MF@CS) composite via the co-precipitation method, which was used to scrutinize the catalytic performance with Methylene Blue (MB) and Malachite Green (MG) dyes by visible light irradiation. The saturation magnetization value of the MF@CS composite is found to be 7.8 emu/g, which is less when compared to that of pristine Fe3O4 (55.7 emu/g) particles. The bandgap of the MF@CS composite is similar to 2.17 eV, which exceeds the bandgap (E-g) of bare MoS2 of 1.80 eV. The maximum color removal of 96.3 % and 93.4 % for MB and MG dyestuffs is recognized in the exposure of the visible spectrum, respectively. At a starting dye dosage of 30 mg/L, 0.1 g/L of MF@CS, a pH level of 8-11, and 70 min of contact with direct light. The photocatalyst provides extremely good durability for a maximum of five phases. Hence, the MF@CS matrix is a viable and appropriate substance for the efficient treatment of effluents containing dye molecules. ⓘ Sirajudheen, Palliyalil; Vigneshwaran, Sivakumar; Thomas, Nygil; Selvaraj, Manickam; Venkatesan, Kumar; Park, Chang Min ⓘ Pocker Sahib Mem Orphanage Coll, Dept Chem, Malappuram 676306, Kerala, India; Kyung Hee Univ, Dept Civil Engn, Environm Syst Lab, Global Campus,1732 Deogyong Daero, Yongin 16705, Gyeonggi Do, South Korea; Nirmalagiri Coll, Dept Chem, Nirmalagiri PO, Kannur 670701, Kerala, India; King Khalid Univ, Fac Sci, Dept Chem, Abha 61413, Saudi Arabia; King Khalid Univ, Coll Pharm, Dept Pharmaceut Chem, Abha 61413, Saudi Arabia; Kyungpook Natl Univ, Dept Environm Engn, 80 Daehak Ro, Daegu 41566, South Korea ⓘ Sirajudheen, Palliyalil/GLT-8188-2022; Venkatesan, Kumar/AAB-1395-2019; Park, Chang Min/CAA-8506-2022; Thomas, Nygil/AAP-5870-2021; Vigneshwaran, Sivakumar/AAE-6278-2022; M., Selvaraj/J-4665-2018 ⓘ 57208340818; 57207105576; 25960482900; 7003615747; 38663737000; 57209588953 ⓘ sirajpalliyalil@gmail.com;cmpark@knu.ac.kr; ⓘ CARBOHYDRATE POLYMERS ⓘ CARBOHYD POLYM ⓘ 0144-8617 1879-1344 335 SCIE CHEMISTRY, APPLIED;CHEMISTRY, ORGANIC;POLYMER SCIENCE ⓘ 2024 12.5 0.9 4.58 2025-05-07 ⓘ 14 14 Chitosan matrix; Magnetic composite; Metal sulphide; Iron oxide; Dye degradation ⓘ GRAPHENE OXIDE NANOSHEET; ANTIBACTERIAL ACTIVITY; REMOVAL ABILITY; LIGHT; NANOCOMPOSITE; PERFORMANCE; ADSORPTION; SUNLIGHT; NANOPARTICLES; MECHANISM ⓘ Chitosan matrix; Dye degradation; Iron oxide; Magnetic composite; Metal sulphide ⓘ Aromatic compounds; Dyes; Energy gap; Layered semiconductors; Magnetite; Molybdenum compounds; Photodegradation; Precipitation (chemical); Saturation magnetization; Sulfur compounds; chitosan; dye; iron oxide; malachite green; methylene blue; polysaccharide; Chitosan composites; Chitosan matrix; Degradation of organic dyes; Dye degradation; Magnetic chitosan; Magnetic composites; Malachite green; Metal sulfides; Methylene Blue; Photocatalytic degradation; article; catalysis; conductance; controlled study; degradation; effluent; ionization; irradiation; nonhuman; pH; precipitation; Chitosan ⓘ English 2024 2024-07-01 10.1016/j.carbpol.2024.122071 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ IT capability and innovation ⓘ We propose that information technology (IT) capability promotes innovation performance by facilitating knowledge-intensive assets. We use firms listed on InformationWeek 500 as a measure of IT capability, finding that IT capability positively impacts firm innovation. We further determine that IT capability is important in innovation, indicating that firms may facilitate knowledge assets by advancing networks and sharing information efficiently. Furthermore, the relationship between IT capability and firm innovation is more pronounced for firms with more intense competition because innovation is more critical in competitive high-tech industries. By fostering knowledge sharing, our study can provide a more nuanced understanding of IT 's role in impacting firm innovation in an increasingly complex environment. This study contributes to the literature on innovation and the economic consequences of IT capability. ⓘ Koo, Kwangjoo; Le, Linh ⓘ Kyungpook Natl Univ, Coll Econ & Business Adm, Daegu, South Korea; Univ Nebraska Omaha, Coll Business Adm, Omaha, NE USA; 80 Daehak Ro, Daegu, South Korea ⓘ ⓘ 57202687309; 57956128700 ⓘ kjkoo@knu.ac.kr;linhle@unomaha.edu; ⓘ TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE ⓘ TECHNOL FORECAST SOC ⓘ 0040-1625 1873-5509 203 SSCI BUSINESS;REGIONAL & URBAN PLANNING ⓘ 2024 13.3 0.9 1.54 2025-05-07 ⓘ 6 6 IT capability; Innovation ⓘ INFORMATION-TECHNOLOGY CAPABILITY; FIRM PERFORMANCE; SYSTEMS; CEOS; SUGGESTIONS; KNOWLEDGE; AGILITY; ENHANCE ⓘ Innovation; IT capability ⓘ Knowledge management; Firm innovation; High tech industry; Information technology capability; Innovation; Innovation performance; Knowledge assets; Knowledge-sharing; Measures of information; Network information; Sharing information; high technology industry; information technology; innovation; knowledge; Competition ⓘ English 2024 2024-06 10.1016/j.techfore.2024.123359 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Thermally-activated gelatin-chitosan-MOF hybrid aerogels for efficient removal of ibuprofen and naproxen ⓘ Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used drugs and have been frequently detected in aquatic environments. This paper demonstrates a thermally-activated gelatin-chitosan and amine-functionalized metal-organic framework (UiO-66-NH2) aerogel (CGC-MOF), which was successfully synthesized for the efficient removal of ibuprofen (IBP) and naproxen (NPX). Various characterization tools were used to systematically analyze the microstructure and physicochemical properties of the synthesized aerogel. In addition, the effect of key reaction parameters as well as batch and continuous-flow fixed-bed column experiments were carried out to elucidate the adsorption process. Several functional groups in the biopolymer network, combined with excellent MOF properties, synergistically couple to form an adsorbent with great performance. The mesoporous aerogel activated at 200 degrees C (CGC-MOF200) exhibited a high specific surface area (819.6 m2/g) that is valuable in providing abundant adsorption active sites that facilitate the efficient adsorption of IBP and NPX. CGC-MOF200 exhibited an excellent removal of IBP and NPX, accounting to 99.28 % and 96.39 %, respectively. The adsorption process followed the pseudo-second-order kinetics and the Freundlich isotherm models, suggesting heterogeneous and chemisorption adsorption processes. Overall, this work provides new and valuable insights into the development of a promising biopolymer-MOF composite aerogel for environmental remediation. ⓘ Kim, Minseok; Njaramba, Lewis Kamande; Yoon, Yeomin; Jang, Min; Park, Chang Min ⓘ Kyungpook Natl Univ, Dept Environm Engn, 80 Daehak Ro, Daegu 41566, South Korea; Univ South Carolina, Dept Civil & Environm Engn, 300 Main St, Columbia, SC 29208 USA; Ewha Womans Univ, Dept Environm Sci & Engn, 52 Ewhayeodae Gil, Seoul 03760, South Korea; Kwangwoon Univ, Dept Environm Engn, 20 Kwangwoon Ro, Seoul 01897, South Korea ⓘ ; Kamande, Lewis/JLL-5435-2023; Yoon, Yeomin/KDP-2253-2024; Park, Chang Min/CAA-8506-2022; Jang, Min/J-2230-2012 ⓘ 59073001500; 57223183206; 7402126688; 36762550700; 57209588953 ⓘ yoony@cec.sc.edu;cmpark@knu.ac.kr; ⓘ CARBOHYDRATE POLYMERS ⓘ CARBOHYD POLYM ⓘ 0144-8617 1879-1344 324 SCIE CHEMISTRY, APPLIED;CHEMISTRY, ORGANIC;POLYMER SCIENCE ⓘ 2024 12.5 0.9 13.36 2025-05-07 ⓘ 42 42 Gelatin; Chitosan; MOF; Ibuprofen; Naproxen ⓘ ADSORPTIVE REMOVAL; AQUEOUS-SOLUTIONS; BATCH; WATER; PHARMACEUTICALS; SELECTIVITY; ISOTHERMS; SCAFFOLDS; MECHANISM; KINETICS ⓘ Chitosan; Gelatin; Ibuprofen; MOF; Naproxen ⓘ Adsorption; Anti-Inflammatory Agents, Non-Steroidal; Chitosan; Gelatin; Ibuprofen; Kinetics; Naproxen; Water Pollutants, Chemical; Adsorption; Aerogels; Biomolecules; Biopolymers; Physicochemical properties; chitosan; gelatin; ibuprofen; naproxen; nonsteroid antiinflammatory agent; Adsorption process; Aquatic environments; Gelatin; Hybrid aerogels; Ibuprofen; Naproxens; Non-steroidal anti-inflammatory drugs; Nonsteroidal anti-inflammatory drugs; Synthesised; Thermally activated; adsorption; chemistry; kinetics; water pollutant; Chitosan ⓘ English 2024 2024-01-15 10.1016/j.carbpol.2023.121436 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Article ⓘ Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial ⓘ Background In Asia, adjuvant chemotherapy after gastrectomy with D2 or more extensive lymph-node dissection is standard treatment for people with pathological stage III gastric or gastro-oesophageal junction (GEJ) cancer. We aimed to assess the efficacy and safety of adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy administered in this setting. Methods ATTRACTION-5 was a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial conducted at 96 hospitals in Japan, South Korea, Taiwan, and China. Eligible patients were aged between 20 years and 80 years with histologically confirmed pathological stage IIIA-C gastric or GEJ adenocarcinoma after gastrectomy with D2 or more extensive lymph-node dissection, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 and available tumour tissue for PD-L1 expression analysis. Patients were randomly assigned (1:1) to receive either nivolumab plus chemotherapy or placebo plus chemotherapy via an interactive web-response system with block sizes of four. Investigational treatment, either nivolumab 360 mg or placebo, was administered intravenously for 30 min once every 3 weeks. Adjuvant chemotherapy was administered as either tegafur-gimeracil-oteracil (S-1) at an initial dose of 40 mg/m(2) per dose orally twice per day for 28 consecutive days, followed by 14 days off per cycle, or capecitabine plus oxaliplatin consisting of an initial dose of intravenous oxaliplatin 130 mg/m(2) for 2 h every 21 days and capecitabine 1000 mg/m(2) per dose orally twice per day for 14 consecutive days, followed by 7 days off treatment. The primary endpoint was relapse-free survival by central assessment. The intention-to-treat population, consisting of all randomly assigned patients, was used for analysis of efficacy endpoints. The safety population, defined as patients who received at least one dose of trial drug, was used for analysis of safety endpoints. This trial is registered with ClinicalTrials.gov (NCT03006705) and is closed. Findings Between Feb 1, 2017, and Aug 15, 2019, 755 patients were randomly assigned to receive either adjuvant nivolumab plus chemotherapy (n=377) or adjuvant placebo plus chemotherapy (n=378). 267 (71%) of 377 patients in the nivolumab group and 263 (70%) of 378 patients in the placebo group were male; 110 (29%) of 377 patients in the nivolumab group and 115 (31%) of 378 patients in the placebo group were female. 745 patients received assigned treatment (371 in the nivolumab plus chemotherapy group; 374 in the placebo plus chemotherapy group), which was the safety population. Median time from first dose to data cutoff was 491 months (IQR 431-567). 3-year relapse-free survival was 684% (95% CI 630-732) in the nivolumab plus chemotherapy group and 653% (599-702) in the placebo plus chemotherapy group; the hazard ratio for relapse-free survival was 090 (9572% CI 069-118; p=044). Treatment-related adverse events occurred in 366 (99%) of 371 patients in the nivolumab plus chemotherapy group and 364 (98%) of 374 patients in the placebo plus chemotherapy group. Discontinuation due to adverse events was more frequent in the nivolumab plus chemotherapy group (34 [9%] of 371 patients) than the placebo plus chemotherapy group (13 [4%] of 374 patients). The most common treatment-related adverse events were decreased appetite, nausea, diarrhoea, neutrophil count decreased, and peripheral sensory neuropathy. Interpretation The results of this trial do not support the addition of nivolumab to postoperative adjuvant therapy for patients with untreated, locally advanced, resectable gastric or GEJ cancer. ⓘ Kang, Yoon-Koo; Terashima, Masanori; Kim, Young-Woo; Boku, Narikazu; Chung, Hyun Cheol; Chen, Jen-Shi; Ji, Jiafu; Yeh, Ta-Sen; Chen, Li-Tzong; Ryu, Min-Hee; Kim, Jong Gwang; Omori, Takeshi; Rha, Sun Young; Kim, Tae Yong; Ryu, Keun Won; Sakuramoto, Shinichi; Nishida, Yasunori; Fukushima, Norimasa; Yamada, Takanobu; Bai, Li-Yuan; Hirashima, Yoshinori; Hagihara, Shunsuke; Nakada, Takashi; Sasako, Mitsuru ⓘ Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; Shizuoka Canc Ctr, Div Gastr Surg, Shizuoka, Japan; Natl Canc Ctr, Ctr Gastr Canc, Surg Dept, Goyang, South Korea; Univ Tokyo Hosp, Inst Med Sci, Dept Oncol & Gen Med, Tokyo, Japan; Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Taoyuan, Taiwan; Chang Gung Univ, Linkou Chang Gung Mem Hosp, Dept Surg, Taoyuan, Taiwan; Beijing Canc Hosp, Dept Gastrointestinal Surg, Beijing, Peoples R China; Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc Res, Kaohsiung, Taiwan; Natl Cheng Kung Univ Hosp, Natl Cheng Kung Univ, Dept Internal Med, Tainan, Taiwan; Kyungpook Natl Univ, Chilgok Hosp, Dept Hematooncol, Daegu, South Korea; Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan; Seoul Natl Univ Hosp, Oncol Dept, Seoul, South Korea; Saitama Med Univ, Int Med Ctr, Dept Gastrointestinal Surg, Saitama, Japan; Keiyukai Sapporo Hosp, Dept Gastrointestinal Surg & Med Oncol, Sapporo, Japan; Yamagata Prefectural Cent Hosp, Dept Surg, Yamagata, Japan; Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan; China Med Univ, China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan; Ono Pharmaceut, Osaka, Japan; Yodogawa Christians Hosp, Dept Surg, Osaka 5330024, Japan ⓘ ; Chen, Jen-Shi/GLV-3349-2022; Chung, Hyun Cheol/AFB-8969-2022; Kang, Yoon-Koo/ABL-4264-2022; Kim, Yuriy/ABD-7016-2020; Kim, Sung-Bae/JXL-8219-2024 ⓘ ⓘ msasako2010@yahoo.co.jp; ⓘ LANCET GASTROENTEROLOGY & HEPATOLOGY ⓘ LANCET GASTROENTEROL ⓘ 2468-1253 9 8 SCIE GASTROENTEROLOGY & HEPATOLOGY ⓘ 2024 38.6 1.0 ⓘ 34 ⓘ OPEN-LABEL; FREE SURVIVAL; ADENOCARCINOMA; CAPECITABINE; OXALIPLATIN; ESOPHAGEAL; PD-L1; S-1; EXPRESSION; SURROGATE ⓘ ⓘ ⓘ English 2024 2024-08 10.1016/s2468-1253(24)00156 ⓘ 바로가기 바로가기 바로가기
○ Article ⓘ Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial ⓘ Background: In Asia, adjuvant chemotherapy after gastrectomy with D2 or more extensive lymph-node dissection is standard treatment for people with pathological stage III gastric or gastro-oesophageal junction (GEJ) cancer. We aimed to assess the efficacy and safety of adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy administered in this setting. Methods: ATTRACTION-5 was a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial conducted at 96 hospitals in Japan, South Korea, Taiwan, and China. Eligible patients were aged between 20 years and 80 years with histologically confirmed pathological stage IIIA–C gastric or GEJ adenocarcinoma after gastrectomy with D2 or more extensive lymph-node dissection, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 and available tumour tissue for PD-L1 expression analysis. Patients were randomly assigned (1:1) to receive either nivolumab plus chemotherapy or placebo plus chemotherapy via an interactive web-response system with block sizes of four. Investigational treatment, either nivolumab 360 mg or placebo, was administered intravenously for 30 min once every 3 weeks. Adjuvant chemotherapy was administered as either tegafur–gimeracil–oteracil (S-1) at an initial dose of 40 mg/m2 per dose orally twice per day for 28 consecutive days, followed by 14 days off per cycle, or capecitabine plus oxaliplatin consisting of an initial dose of intravenous oxaliplatin 130 mg/m2 for 2 h every 21 days and capecitabine 1000 mg/m2 per dose orally twice per day for 14 consecutive days, followed by 7 days off treatment. The primary endpoint was relapse-free survival by central assessment. The intention-to-treat population, consisting of all randomly assigned patients, was used for analysis of efficacy endpoints. The safety population, defined as patients who received at least one dose of trial drug, was used for analysis of safety endpoints. This trial is registered with ClinicalTrials.gov (NCT03006705) and is closed. Findings: Between Feb 1, 2017, and Aug 15, 2019, 755 patients were randomly assigned to receive either adjuvant nivolumab plus chemotherapy (n=377) or adjuvant placebo plus chemotherapy (n=378). 267 (71%) of 377 patients in the nivolumab group and 263 (70%) of 378 patients in the placebo group were male; 110 (29%) of 377 patients in the nivolumab group and 115 (31%) of 378 patients in the placebo group were female. 745 patients received assigned treatment (371 in the nivolumab plus chemotherapy group; 374 in the placebo plus chemotherapy group), which was the safety population. Median time from first dose to data cutoff was 49·1 months (IQR 43·1–56·7). 3-year relapse-free survival was 68·4% (95% CI 63·0–73·2) in the nivolumab plus chemotherapy group and 65·3% (59·9–70·2) in the placebo plus chemotherapy group; the hazard ratio for relapse-free survival was 0·90 (95·72% CI 0·69–1·18; p=0·44). Treatment-related adverse events occurred in 366 (99%) of 371 patients in the nivolumab plus chemotherapy group and 364 (98%) of 374 patients in the placebo plus chemotherapy group. Discontinuation due to adverse events was more frequent in the nivolumab plus chemotherapy group (34 [9%] of 371 patients) than the placebo plus chemotherapy group (13 [4%] of 374 patients). The most common treatment-related adverse events were decreased appetite, nausea, diarrhoea, neutrophil count decreased, and peripheral sensory neuropathy. Interpretation: The results of this trial do not support the addition of nivolumab to postoperative adjuvant therapy for patients with untreated, locally advanced, resectable gastric or GEJ cancer. Funding: Ono Pharmaceutical and Bristol Myers Squibb. © 2024 Elsevier Ltd ⓘ Kang, Yoon-Koo; Terashima, Masanori; Kim, Young-Woo; Boku, Narikazu; Chung, Hyun Cheol; Chen, Jen-Shi; Ji, Jiafu; Yeh, Ta-Sen; Chen, Li-Tzong; Ryu, Min-Hee; Kim, Jong Gwang; Omori, Takeshi; Rha, Sun Young; Kim, Tae Yong; Ryu, Keun Won; Sakuramoto, Shinichi; Nishida, Yasunori; Fukushima, Norimasa; Yamada, Takanobu; Bai, Li-Yuan; Hirashima, Yoshinori; Hagihara, Shunsuke; Nakada, Takashi; Sasako, Mitsuru ⓘ Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea; Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan; Surgical Department, Center for Gastric Cancer, National Cancer Center, Goyang, South Korea; Department of Oncology and General Medicine, Institute of Medical Science, University of Tokyo Hospital, Tokyo, Japan; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan; Department of Gastrointestinal Surgery, Beijing Cancer Hospital, Beijing, China; Department of Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan; Centre for Cancer Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan City, Taiwan; Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea; Department of Hemato-Oncology, Chilgok Hospital, Kyungpook National University, Daegu, South Korea; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea; Oncology Department, Seoul National University Hospital, Seoul, South Korea; Surgical Department, Center for Gastric Cancer, National Cancer Center, Goyang, South Korea; Department of Gastrointestinal Surgery, International Medical Center, Saitama Medical University, Saitama, Japan; Department of Gastrointestinal Surgery and Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan; Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan; Division of Hematology and Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan; Ono Pharmaceutical, Osaka, Japan; Ono Pharmaceutical, Osaka, Japan; Ono Pharmaceutical, Osaka, Japan; Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan ⓘ ⓘ 7402784198; 7102829215; 57215377843; 55359026700; 7404006815; 35075804900; 7201362473; 7201657662; 7409440415; 7101754860; 59501049300; 8632206000; 7006023235; 57201336410; 55667555300; 6602596865; 57202598227; 13702932100; 7405973313; 7201957490; 24576628600; 57226591305; 59179741100; 55707897200 ⓘ msasako2010@yahoo.co.jp; ⓘ The Lancet Gastroenterology and Hepatology ⓘ LANCET GASTROENTEROL ⓘ N/A 2468-1253 9 8 SCIE GASTROENTEROLOGY & HEPATOLOGY ⓘ 2024 38.6 1.0 12.47 2025-05-07 ⓘ 33 ⓘ ⓘ ⓘ Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Nivolumab; Stomach Neoplasms; Treatment Outcome; adjuvant; capecitabine; creatinine; docetaxel; dopamine 2 receptor; famotidine; nivolumab; oxaliplatin; placebo; antineoplastic agent; nivolumab; adjuvant chemotherapy; aged; analysis; appetite; Article; chemotherapy; controlled study; diarrhea; double blind procedure; ECOG Performance Status; esophagus cancer; female; gastrectomy; histology; human; lymph node dissection; male; multicenter study; nausea; neutrophil count; overall survival; phase 3 clinical trial; randomized controlled trial; statistical analysis; stomach cancer; Taiwan; tumor volume; adenocarcinoma; adult; cancer staging; clinical trial; drug therapy; esophagus tumor; gastroesophageal junction; middle aged; pathology; procedures; stomach tumor; surgery; treatment outcome; very elderly ⓘ English Final 2024 10.1016/s2468-1253(24)00156-0 ⓘ 바로가기 바로가기 바로가기
○ ○ Review ⓘ Biomass-derived materials for energy storage and electrocatalysis: recent advances and future perspectives ⓘ Over the last decade, there has been significant effort dedicated to both fundamental research and practical applications of biomass-derived materials, including electrocatalytic energy conversion and various functional energy storage devices. Beyond their sustainability, eco-friendliness, structural diversity, and biodegradability, biomass-derived materials provide additional benefits, including naturally organized hierarchical structures, rich surface properties, and an abundance of heteroatoms. These characteristics make them appealing candidates for effective energy storage and electrocatalytic energy conversion applications. This review explores the recent advancements in biomass-derived materials for energy storage system (ESS), including supercapacitors and electrocatalytic reactions. We also address the scientific and technical hurdles associated with these materials and outline potential avenues for future research on biomass-based energy conversion applications. By emphasizing the significance of controllable structural designs and modifications, we highlight their crucial roles in advancing this field. Biomass-derived materials offer sustainable solutions for energy storage & conversion.Challenges include fabrication of high-quality biomass-derived carbon materials.Future research directions aim to optimize structural designs for enhanced performance. ⓘ Nguyen, Van-Toan; Cho, Kanghee; Choi, Yujin; Hwang, Byungwook; Park, Young-Kwon; Nam, Hyungseok; Lee, Doyeon ⓘ Hanbat Natl Univ, Dept Civil & Environm Engn, Daejeon 34158, South Korea; Inha Univ, Dept Chem & Chem Engn, Incheon 22212, South Korea; Korea Inst Energy Res, Climate Change Res Div, Daejeon 34129, South Korea; Univ Seoul, Sch Environm Engn, Seoul 02504, South Korea; Kyungpook Natl Univ, Sch Mech Engn, Daegu 41566, South Korea; Korea Atom Energy Res Inst, Nucl Chem Res Div, Daejeon 34057, South Korea ⓘ ⓘ 57193268087; 58527209800; 57734617200; 44461423600; 16029749100; 57190418228; 55881252900 ⓘ catalica@uos.ac.kr;namhs219@knu.ac.kr;dylee82@hanbat.ac.kr; ⓘ BIOCHAR ⓘ BIOCHAR ⓘ 2524-7972 2524-7867 6 1 SCIE ENVIRONMENTAL SCIENCES;SOIL SCIENCE ⓘ 2024 13.5 1.0 0.47 2025-05-07 ⓘ 8 9 Electrocatalysis; Energy conversion; Energy storage device; Biomass; Biomass-derived carbon materials ⓘ OXYGEN REDUCTION REACTION; POROUS CARBON SHEETS; ONE-STEP PRODUCTION; N-DOPED CARBON; HIGH-PERFORMANCE; CO2 REDUCTION; SUPERCAPACITOR ELECTRODES; CHEMICAL ACTIVATION; HIGHLY EFFICIENT; STABLE ELECTROCATALYST ⓘ Biomass; Biomass-derived carbon materials; Electrocatalysis; Energy conversion; Energy storage device ⓘ ⓘ English 2024 2024-11-11 10.1007/s42773-024-00388-1 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Review ⓘ Light-Material Interactions Using Laser and Flash Sources for Energy Conversion and Storage Applications ⓘ This review paper provides a comprehensive analysis of light-material interaction (LMI) parameters, offering insights into their significance in material processing.It examines a wide array of photothermal and photochemical processes, showcasing their versatility in creating advanced materials for energy conversion and storage applications.The review presents a multidisciplinary approach to advancing LMI technologies and highlights their potential contribution to the commercialization of future energy conversion and storage systems. This review provides a comprehensive overview of the progress in light-material interactions (LMIs), focusing on lasers and flash lights for energy conversion and storage applications. We discuss intricate LMI parameters such as light sources, interaction time, and fluence to elucidate their importance in material processing. In addition, this study covers various light-induced photothermal and photochemical processes ranging from melting, crystallization, and ablation to doping and synthesis, which are essential for developing energy materials and devices. Finally, we present extensive energy conversion and storage applications demonstrated by LMI technologies, including energy harvesters, sensors, capacitors, and batteries. Despite the several challenges associated with LMIs, such as complex mechanisms, and high-degrees of freedom, we believe that substantial contributions and potential for the commercialization of future energy systems can be achieved by advancing optical technologies through comprehensive academic research and multidisciplinary collaborations. ⓘ Park, Jung Hwan; Pattipaka, Srinivas; Hwang, Geon-Tae; Park, Minok; Woo, Yu Mi; Kim, Young Bin; Lee, Han Eol; Jeong, Chang Kyu; Zhang, Tiandong; Min, Yuho; Park, Kwi-Il; Lee, Keon Jae; Ryu, Jungho ⓘ Kumoh Natl Inst Technol, Dept Mech Engn, Dept Aeronaut Mech & Elect Convergence Engn, 61 Daehak Ro, Gumi 39177, Gyeongbuk, South Korea; Pukyong Natl Univ, Dept Mat Sci & Engn, 45 Yongso Ro, Busan 48513, South Korea; Lawrence Berkeley Natl Lab, Energy Technol Area, Berkeley, CA 94720 USA; Korea Adv Inst Sci & Technol KAIST, Dept Mat Sci & Engn, 291 Daehak Ro, Daejeon 34141, South Korea; Jeonbuk Natl Univ, Div Adv Mat Engn, Jeonju 54896, Jeonbuk, South Korea; Harbin Univ Sci & Technol, Sch Elect & Elect Engn, Harbin 150080, Peoples R China; Harbin Univ Sci & Technol, Key Lab Engn Dielect & Its Applicat, Minist Educ, Harbin 150080, Peoples R China; Kyungpook Natl Univ, Dept Mat Sci & Met Engn, 80 Daehak ro, Daegu 41566, South Korea; Yeungnam Univ, Sch Mat Sci & Engn, Gyongsan Si 38541, Gyeongsangbuk D, South Korea ⓘ Ryu, Jungho/LXU-4081-2024; Park, Kwiil/LKN-9445-2024; Lee, Han/AAS-6899-2020; Jeong, Chang/H-5275-2016; Pattipaka, Srinivas/P-2993-2019 ⓘ 55716954000; 57189258366; 36704574900; 57212683444; 58407529000; 59289875000; 56415504500; 55961876600; 56431572600; 36782804100; 35280874200; 58620007700; 57201603501 ⓘ kipark@knu.ac.kr;keonlee@kaist.ac.kr;jhryu@ynu.ac.kr; ⓘ NANO-MICRO LETTERS ⓘ NANO-MICRO LETT ⓘ 2311-6706 2150-5551 16 1 SCIE MATERIALS SCIENCE, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY;PHYSICS, APPLIED ⓘ 2024 36.3 1.0 0.41 2025-05-07 ⓘ 4 5 Light; Light-material interaction; Nanomaterials; Energy conversion and storage devices ⓘ SENSITIZED SOLAR-CELLS; THIN-FILM TRANSISTORS; HIGH-PERFORMANCE; INDUCED CRYSTALLIZATION; ELECTRICAL-PROPERTIES; AMORPHOUS-SILICON; LI+ CONDUCTIVITY; GRAPHITE OXIDE; GRAPHENE OXIDE; HIGH-CAPACITY ⓘ Energy conversion and storage devices; Light; Light–material interaction; Nanomaterials ⓘ Laser materials processing; Energy conversion and storage device; Energy conversion and storages; Flash light; Fluences; Interaction parameters; Interaction time; Laser lights; Light materials; Light–material interaction; Material interactions; Energy harvesting ⓘ English 2024 2024-12 10.1007/s40820-024-01483-5 ⓘ 바로가기 바로가기 바로가기 바로가기
페이지 이동: